ENERGI F703

Drug Profile

ENERGI F703

Alternative Names: ENERGIF703

Latest Information Update: 14 Jul 2017

Price : $50

At a glance

  • Originator Energenesis Biomedical
  • Class
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer

Most Recent Events

  • 15 Mar 2017 Phase-II clinical trials in Diabetic foot ulcer in Taiwan (Topical) (NCT02672436)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top